FDA Approves Genentech's HEMLIBRA, (Emicizumab-KXWH) for Hemophilia A with Inhibitors

Note: The following is an edited excerpt from a press release from Genentech. To read the press release in it’s entirety, click HERE. Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved HEMLIBRA®Â (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes […]